{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"20.600","floor":"18.400"},"ipodate":{"start":"2020-06-24 00:00:00","end":"2020-06-30 00:00:00"},"minimumcapital":"10403.80","subscribed":"69.21","marketcap":"269.98億","H_marketcap":"40.50億","pe":"22.89","codesrate":"40.00","link":"https://staticpdf.iqdii.com/stockdata/notice/09989/2020/2020062400098_c.pdf","ipopricing":"18.400","resultdate":"2020-07-07 00:00:00","enddate":"2020-06-30 00:00:00","listeddate":"2020-07-08 00:00:00","issuenumber":"22009.45萬","issuenumberhK":"8803.80萬","issuenumberother":"13205.65萬","grayprice":"18.40","sponsors":"高盛(亞洲)有限責任公司,摩根士丹利亞洲有限公司","raisemoney":"380570.00萬","use":"1、約30.0%或約1,141.7百萬港元，用于改善資本結構及償還現有債務；\n2、約30.0%或約1,141.7百萬港元，用于我們在歐盟及其他全球市場（如中國）拓展銷售及營銷網絡以及基礎設施；\n3、約20.0%或約761.1百萬港元，用于提升我們的開發及生產能力，并擴大我們向賽灣生物提供的產品及服務；\n4、約20.0%或約761.1百萬港元，用于創新藥的投資。","shares":500,"leadagent":"高盛(亞洲)有限責任公司,摩根士丹利亞洲有限公司,招銀國際融資有限公司,海通國際證券有限公司,中銀國際亞洲有限公司,中信里昂證券有限公司,工銀國際證券有限公司,浦銀國際融資有限公司,金聯證券有限公司","bookrunners":"高盛(亞洲)有限責任公司,摩根士丹利亞洲有限公司,招銀國際融資有限公司,海通國際證券有限公司,中銀國際亞洲有限公司,中信里昂證券有限公司,工銀國際融資有限公司,浦銀國際融資有限公司","coordinator":"高盛(亞洲)有限責任公司,摩根士丹利亞洲有限公司,招銀國際融資有限公司","firstDayOpen":"18.46","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E09989","name":"海普瑞","fullname":"深圳市海普瑞藥業集團股份有限公司"},"institutioninfo":{"principaloffice":"深圳市南山區郎山路21號","registrars":"卓佳證券登記有限公司","registrarstel":"(852) 2980 1333","chairman":"李鋰","secretary":"談煊,陳詩婷","telephone":"(86755) 2698 0311","substantialshareholders":"樂仁科技(32.31%),金田土(27.81%)","principalactivities":"公司是領先的中國制藥公司，在全球擁有制藥領域、創新生物科技領域及CDMO領域的業務。","website":"http://www.hepalink.com"},"managerinfo":[{"managername":"李鋰","post":"董事長兼執行董事","rankno":1},{"managername":"李坦","post":"副總經理兼執行董事","rankno":2},{"managername":"單宇","post":"總經理兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"OrbiMed Funds","shareholding":"21,049,500.0","percentage":9.56,"ReleaseDate":"2021-01-08 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"AVICT Global Holdings Limited","shareholding":"12,629,500.0","percentage":5.74,"ReleaseDate":"2021-01-08 00:00:00","relatedparty":"深圳市普泰投資發展有限公司","subsidiary":["AVICT Global Holdings Limited"],"InverstorType":"公司"},{"institutionname":"歐萬達基金管理有限公司","shareholding":"6,314,500.0","percentage":2.87,"ReleaseDate":"2021-01-08 00:00:00","relatedparty":"James Chen","subsidiary":["歐萬達基金管理有限公司"],"InverstorType":"公司"},{"institutionname":"3W Funds","shareholding":"4,209,500.0","percentage":1.91,"ReleaseDate":"2021-01-08 00:00:00","relatedparty":"3W Fund Management Limited","subsidiary":["3W Funds"],"InverstorType":"基金"}],"TotalShareholdingPercentage":21.04},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":14}